In a crossover bioequivalence study, some subjects will drop out of the study after (or even before) administration of the first treatment.
Manage dropouts by dosing several more than the required number of subjects in the first phase and specifying in the protocol how the requisite number of subjects will be chosen from those remaining in the study, for dosing in the second phase.
